References

1. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83:25F-29F.

2. Wilson PWF, Kannel WB, Silbershatz H, D’Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104-1109.

3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.

4. Bedinghaus J, Leshan L, Diehr S. Coronary artery disease prevention: what’s different for women? Am Fam Physician. 2001;63:1393-1400.

5. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e171.

6. Wenger NK. Clinical characteristics of coronary heart disease in women: emphasis on gender differences. Cardiovasc Res. 2002;53:558-567.

7. Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction: an update on the Framingham study. N Engl J Med. 1984;311:1144-1147.

8. Heart disease and African Americans. 2007. The Office of Minority Health. Available at: http://www.omhrc.gov/templates/content.aspx?ID=3018. Accessed July 24, 2007.

9. American Heart Association. Heart Disease and Stroke Statistics—2006 Update. Dallas, Tex: American Heart Association; 2006.

10. Bruce IN, , Gladman DD, Urowitz MB. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am. 2000;26:257-278.

11. Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Isomäki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol. 1995;22:1065-1067.

12. Manzi S. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis. 2000;59:321-325.

13. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112:3337-3347.

14. DeLuca AJ, Kaplan S, Aronow WS, et al. Comparison of prevalence of unrecognized myocardial infarction and of silent myocardial ischemia detected by a treadmill exercise sestamibi stress test in patients with versus without diabetes mellitus. Am J Cardiol. 2006;98:1045-1046.

15. Wackers FJTh, Young LH, Inzucchi SE, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care. 2004;27:1954-1961.

16. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.

17. Miller TD, Rajagopalan N, Hodge DO, Frye RL, Gibbons RJ. Yield of stress single-photon emission computed tomography in asymptomatic patients with diabetes. Am Heart J. 2004;147:890-896.

18. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293:1861-1867.

19. Carnethon MR, Gulati M, Greenland P. Prevalence and cardiovascular disease correlates of low cardiorespiratory fitness in adolescents and adults. JAMA. 2005;294:2981-2988.

20. Centers for Disease Control and Prevention. Prevalence of diabetes among Hispanics—selected areas, 1998-2002. MMWR. 2004;53:941-944.

21. Kraja AT, Rao DC, Weder AB, et al. An evaluation of the metabolic syndrome in a large multi-ethnic study: the Family Blood Pressure Program. Nutr Metab. 2005;2:17.

22. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.

23. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999;282:1519-1522.

24. Schoenborn CA, Adams PF, Barnes PM, Vickerie JL, Schiller JS. Health behaviors of adults: United States, 1999–2001. Vital Health Stat 10. 2004:1-79.

25. Aldrich L, Variyam JN. Acculturation erodes the diet quality of US Hispanics. Food Review. 2000;23:51-55.

26. Hubert HB, Snider J, Winkleby MA. Health status, health behaviors, and acculturation factors associated with overweight and obesity in Latinos from a community and agricultural labor camp survey. Prev Med. 2005;40:642-651.

27. Mainous AG 3rd, Majeed A, Koopman RJ, et al. Acculturation and diabetes among Hispanics: evidence from the 1999-2002 National Health and Nutrition Examination Survey. Public Health Rep. 2006;121:60-66.

28. US Census Bureau American Fact Finder Fact Sheet. Census 2000.
http://factfinder.census.gov/servlet/SAFFFacts?_event=&geo_id=01000US
&_geoContext=01000US&_street=&_county=&_cityTown=&_state=&_zip=
&_lang=en&_sse=on&ActiveGeoDiv=&_useEV=&pctxt=fph&pgsl=010
&_submenuId=factsheet_1&ds_name=ACS_2007_3YR_SAFF&_ci_nbr=null&
qr_name=null&reg=&_keyword=&_industry=. Accessed July 13, 2009.

29. Jacobs EA, Shepard DS, Suaya JA, Stone E-L. Overcoming language barriers in health care: costs and benefits of interpreter services. Am J Public Health. 2004;94:866-869.

30. Centers for Disease Control and Prevention. Access to health-care and preventive services among Hispanics and non-Hispanics—United States, 2001-2002. MMWR. 2004;53:937-941.

31. Health care experiences. Pew Hispanic Center, March 2004. Available at: http://pewhispanic.org/files/reports/15.8.pdf. Accessed August 21, 2007.

Intravenous Adenoscan is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.

IMPORTANT SAFETY INFORMATION

Adenoscan is contraindicated in patients with second- or third-degree AV block, unless these patients have a functioning artificial pacemaker, sinus node disease, and known or suspected bronchoconstrictive or bronchospastic lung disease.

Fatal cardiac arrest, sustained ventricular tachycardia (requiring resuscitation), and nonfatal myocardial infarction have been reported coincident with Adenoscan infusion. Patients with unstable angina may be at greater risk. Appropriate resuscitative measures should be available.

Adenoscan is a potent peripheral vasodilator and can cause significant hypotension. The risk of hypotension may be higher in patients with cardiac or cerebrovascular insufficiency.

Adenoscan exerts a direct depressant effect on the SA and AV nodes and has the potential to cause first-, second- or third-degree AV block, or sinus bradycardia.

Increases in systolic and diastolic pressure have been observed.

Adenosine receptor agonists, including Adenoscan, may cause bronchoconstriction and respiratory compromise.

Atrial fibrillation has been reported in patients with Adenoscan infusion and may last from a few seconds to hours, however, patients spontaneously converted to normal sinus rhythm.

Most common adverse reactions (≥5%) to Adenoscan are flushing, chest discomfort, dyspnea, headache, discomfort of the throat, neck, or jaw, gastrointestinal discomfort, and lightheadedness/dizziness. Side effects with Adenoscan usually resolve quickly when the infusion is discontinued, although delayed or persistent effects have been observed.

Please see full prescribing information.
About Astellas   |   Privacy Policy   |   Terms of Use
©2009 Astellas Pharma US, Inc. All rights reserved.